Your browser doesn't support javascript.
Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population.
Bednarski, Eva; Del Rio Estrada, Perla M; DaSilva, Justin; Boukadida, Celia; Zhang, Fengwen; Luna-Villalobos, Yara A; Rodríguez-Rangel, Ximena; Pitén-Isidro, Elvira; Luna-García, Edgar; Díaz Rivera, Dafne; López-Sánchez, Dulce M; Tapia-Trejo, Daniela; Soto-Nava, Maribel; Astorga-Castañeda, Myriam; Martínez-Moreno, José O; Urbina-Granados, Guadalupe S; Jiménez-Jacinto, José A; Serna Alvarado, Francisco J; Enriquez-López, Yerania E; López-Arellano, Oliva; Reyes-Teran, Gustavo; Bieniasz, Paul D; Avila-Rios, Santiago; Hatziioannou, Theodora.
  • Bednarski E; Laboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA.
  • Del Rio Estrada PM; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosío Villegas, Mexico City, Mexico.
  • DaSilva J; Laboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA.
  • Boukadida C; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosío Villegas, Mexico City, Mexico.
  • Zhang F; Laboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA.
  • Luna-Villalobos YA; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosío Villegas, Mexico City, Mexico.
  • Rodríguez-Rangel X; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosío Villegas, Mexico City, Mexico.
  • Pitén-Isidro E; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosío Villegas, Mexico City, Mexico.
  • Luna-García E; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosío Villegas, Mexico City, Mexico.
  • Díaz Rivera D; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosío Villegas, Mexico City, Mexico.
  • López-Sánchez DM; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosío Villegas, Mexico City, Mexico.
  • Tapia-Trejo D; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosío Villegas, Mexico City, Mexico.
  • Soto-Nava M; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosío Villegas, Mexico City, Mexico.
  • Astorga-Castañeda M; Jurisdicción Sanitaria Coyoacán, Servicios de Salud Pública de la Ciudad de México, Mexico City, Mexico.
  • Martínez-Moreno JO; Jurisdicción Sanitaria Coyoacán, Servicios de Salud Pública de la Ciudad de México, Mexico City, Mexico.
  • Urbina-Granados GS; Jurisdicción Sanitaria Cuajimalpa, Servicios de Salud Pública de la Ciudad de México, Mexico City, Mexico.
  • Jiménez-Jacinto JA; Jurisdicción Sanitaria Magdalena Contreras, Servicios de Salud Pública de la Ciudad de México, Mexico City, Mexico.
  • Serna Alvarado FJ; Jurisdicción Sanitaria Iztapalapa, Servicios de Salud Pública de la Ciudad de México, Mexico City, Mexico.
  • Enriquez-López YE; Jurisdicción Sanitaria Tlalpan, Servicios de Salud Pública de la Ciudad de México, Mexico City, Mexico.
  • López-Arellano O; Secretaría de Salud, Mexico City, Mexico.
  • Reyes-Teran G; Institutos Nacionales de Salud y Hospitales de Alta Especialidad, Secretaría de Salud de México, Mexico City, Mexico.
  • Bieniasz PD; Laboratory of Retrovirology, The Rockefeller Universitygrid.134907.8, New York, New York, USA.
  • Avila-Rios S; Howard Hughes Medical Institute, Chevy Chase, Maryland, USA.
  • Hatziioannou T; Centro de Investigación en Enfermedades Infecciosas, Instituto Nacional de Enfermedades Respiratoriasgrid.419179.3 Ismael Cosío Villegas, Mexico City, Mexico.
mBio ; 13(4): e0084022, 2022 08 30.
Article in English | MEDLINE | ID: covidwho-1901929
ABSTRACT
Global population immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is accumulating through heterogeneous combinations of infection and vaccination. Vaccine distribution in low- and middle-income countries has been variable and reliant on diverse vaccine platforms. We studied B-cell immunity in Mexico, a middle-income country where five different vaccines have been deployed to populations with high SARS-CoV-2 incidences. Levels of antibodies that bound a stabilized prefusion spike trimer, neutralizing antibody titers, and memory B-cell expansion correlated with each other across vaccine platforms. Nevertheless, the vaccines elicited variable levels of B-cell immunity, and the majority of recipients had undetectable neutralizing activity against the recently emergent omicron variant. SARS-CoV-2 infection, experienced before or after vaccination, potentiated B-cell immune responses and enabled the generation of neutralizing activity against omicron and SARS-CoV for all vaccines in nearly all individuals. These findings suggest that broad population immunity to SARS-CoV-2 will eventually be achieved but by heterogeneous paths. IMPORTANCE The majority of studies on SARS-CoV-2 vaccine-elicited immunity and immune evasion have focused on single vaccines corresponding to those distributed in high-income countries. However, in low- and middle-income countries, vaccine deployment has been far less uniform. It is therefore important to determine the levels of immunity elicited by vaccines that have been deployed globally. Such data should help inform policy. Thus, this paper is very much a "real-world" study that focuses on a middle-income country, Mexico, in which five different vaccines based on mRNA, adenovirus, and inactivated-virus platforms have been extensively deployed, while (as documented in our study) SARS-CoV-2 variants with increasing degrees of immune evasiveness have propagated in the Mexican population, culminating in the recent emergence of B.1.1.529 (omicron).
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Experimental Studies / Observational study Topics: Vaccines / Variants Limits: Humans Language: English Journal: MBio Year: 2022 Document Type: Article Affiliation country: Mbio.00840-22

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Experimental Studies / Observational study Topics: Vaccines / Variants Limits: Humans Language: English Journal: MBio Year: 2022 Document Type: Article Affiliation country: Mbio.00840-22